QurieGen utilizes a high-throughput proprietary platform that combines single-cell genomics and data science to create predictive models of disease biology and drug response. This approach addresses the inefficiencies in pharmaceutical R&D by enabling earlier predictions of drug efficacy and patient suitability, thereby reducing costs and time in drug development.
Funding
€2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmaceutical research and development faces high costs and frequent setbacks due to the difficulty in predicting drug efficacy and patient suitability early in the development process. Traditional trial-and-error testing methods often fail to reveal novel biological insights, leading to inefficient drug discovery and development pipelines.
Solution
QurieGen offers a platform that combines single-cell genomics and data science to create predictive models of disease biology and drug response. By mapping cellular responses using a high-throughput approach, QurieGen aims to improve the efficiency of pharmaceutical R&D. The platform is designed to enable earlier predictions of drug efficacy and patient suitability, potentially reducing costs and time in drug development. QurieGen's approach seeks to unravel novel biology and outperform traditional testing methods.
Target Audience
QurieGen's primary customers are pharmaceutical companies and research institutions involved in drug discovery and development.
Features
- High-throughput proprietary platform for mapping cellular responses
- Integration of single-cell genomics and data science
- Predictive models of disease biology and drug response
- Identification of new drug targets
- Strategic research partnerships tailored to partner priorities
- Flexible experimental approach